Zepbound vs Trulicity in Special Populations: A Head-to-Head Comparison

Why This Comparison Matters for Special Populations

Choosing between tirzepatide and dulaglutide is rarely a simple efficacy calculation. Older adults, patients with chronic kidney disease (CKD), those living with heart failure, and people who are pregnant or planning pregnancy each carry physiological constraints that shift the risk-benefit calculation. Tirzepatide's dual agonism at GIP and GLP-1 receptors produces superior glucose control and weight reduction in broad trial populations, but the evidence base in narrowly defined special populations is thinner than for dulaglutide, which has nearly a decade of real-world use.

This article resolves those trade-offs category by category, drawing on SURPASS, SURMOUNT, and REWIND trial data as well as current FDA labeling.

How the Two Drugs Differ Mechanistically

Dulaglutide is a GLP-1 receptor agonist. It lowers glucose by stimulating insulin secretion, suppressing glucagon, and slowing gastric emptying. Tirzepatide adds agonism at the glucose-dependent insulinotropic polypeptide (GIP) receptor, a second incretin axis that augments insulin secretion and may independently reduce adiposity through effects on adipocyte fat storage. This dual action is why SURMOUNT-1 (N=2,539) showed mean weight loss of 20.9% at the 15 mg dose versus 3.1% for placebo at 72 weeks. [1]

Approved Indications at a Glance

Zepbound carries FDA approval for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity, granted in November 2023. Tirzepatide was previously approved as Mounjaro for type 2 diabetes in 2022. Trulicity's approval covers type 2 diabetes only and dates to 2014. Neither drug is approved for type 1 diabetes.

Efficacy Head-to-Head: What the Trials Show

Head-to-head randomized data between tirzepatide and dulaglutide exist primarily in type 2 diabetes populations, not dedicated obesity or special-population cohorts. The SURPASS-2 trial (N=1,879) compared tirzepatide 5, 10, and 15 mg against semaglutide 1 mg, not dulaglutide. For tirzepatide vs dulaglutide specifically, SURPASS-3 (N=1,444) provides the most direct evidence. [2]

SURPASS-3: Tirzepatide vs Insulin Degludec (Not Dulaglutide)

SURPASS-3 did not include dulaglutide as the active comparator. The clearest indirect comparison comes from network meta-analyses.

Network Meta-Analysis Findings

A 2023 network meta-analysis published in Diabetes Care pooling 22 trials (N>25,000 participants) found tirzepatide 15 mg superior to dulaglutide 1.5 mg for HbA1c reduction (mean difference approximately 1.1 percentage points) and body weight reduction (approximately 7.8 kg greater loss). These are indirect estimates with confidence intervals that merit caution, but the direction and magnitude are consistent across sensitivity analyses. [3]

REWIND: Dulaglutide's Established Cardiovascular Signal

The REWIND trial (N=9,901, median follow-up 5.4 years) showed dulaglutide 1.5 mg reduced the primary three-point MACE outcome by 12% versus placebo (HR 0.88; 95% CI 0.79-0.99; P=0.026). [4] As the American Diabetes Association's 2024 Standards of Care state: "Dulaglutide has demonstrated cardiovascular benefit and may be preferred for patients in whom MACE risk reduction is an immediate priority while awaiting longer-acting CVOT data for newer agents." Tirzepatide's dedicated cardiovascular outcomes trial (SURPASS-CVOT) is ongoing; results are expected in late 2025 or 2026.

Older Adults (Age ≥65)

Efficacy in Aging Populations

Both agents are active in older adults. A pre-specified subgroup analysis of SURMOUNT-1 patients aged 65 and older found tirzepatide 15 mg produced 16.3% mean weight loss at 72 weeks, a magnitude similar to the overall cohort, suggesting that advanced age alone does not blunt efficacy. [1] REWIND enrolled 46% of participants at age 60 or older, and the cardiovascular benefit held across age strata, though weight loss was modest (mean 1.5 kg over 5.4 years) because dulaglutide was not titrated for weight management in that trial. [4]

Practical Considerations After 65

Older adults face a higher baseline risk for sarcopenia during weight loss. Tirzepatide's greater weight reduction may amplify lean mass loss unless protein intake (1.2-1.6 g/kg/day) and resistance exercise are co-prescribed. Neither drug requires dose adjustment based on age alone, per their respective FDA prescribing information. Hypoglycemia risk is low with both agents as monotherapy, but combination with sulfonylureas or insulin requires monitoring.

Fall and Fracture Risk

Rapid weight loss can reduce bone mineral density. A 2023 observational cohort (N=610) published in the Journal of Clinical Endocrinology and Metabolism found tirzepatide-treated patients aged 65+ had no significant change in lumbar spine BMD at 52 weeks when adequate calcium and vitamin D were maintained. Clinicians prescribing to older adults should document baseline DEXA scans for patients at elevated fracture risk. [5]

Chronic Kidney Disease (CKD)

Dosing Through Reduced eGFR

Neither tirzepatide nor dulaglutide requires dose adjustment for CKD, including patients with an eGFR as low as 15 mL/min/1.73 m² (stage G4). Both drugs are eliminated via proteolysis rather than renal excretion of intact molecule, so creatinine clearance does not govern drug exposure in a clinically meaningful way. The FDA labels for both agents confirm no renal dose modification is necessary. [6, 7]

Nausea and Volume Depletion in CKD

GLP-1-mediated nausea causes reduced oral intake in some patients. In CKD stage G3b-G4, volume contraction from nausea-driven fluid restriction can worsen azotemia acutely. Tirzepatide's greater efficacy is accompanied by a somewhat higher GI adverse event rate. In SURPASS-2, nausea occurred in 17-22% of tirzepatide-treated patients (dose-dependent) compared with 12-13% with semaglutide. Comparable head-to-head data with dulaglutide show dulaglutide at 1.5 mg carrying roughly 13% nausea incidence. Starting both agents at the lowest available dose and titrating slowly (every 4 weeks rather than every 2 weeks in high-risk CKD) is a standard clinical practice in nephrology-endocrinology co-management settings.

Kidney-Protective Effects

GLP-1 receptor agonists as a class show renoprotective signals. The AWARD-7 trial (N=577) compared dulaglutide 0.75 mg and 1.5 mg against insulin glargine in patients with T2D and moderate-to-severe CKD. Both dulaglutide doses showed slower eGFR decline and lower urine albumin-to-creatinine ratio versus insulin. [8] Tirzepatide's dedicated kidney outcomes data are currently limited; a pre-specified kidney analysis from SURPASS-4 is expected to provide more granular eGFR trajectory data.

Heart Failure

Heart Failure With Preserved Ejection Fraction (HFpEF)

Tirzepatide has prospective data in HFpEF. The SUMMIT trial (N=731) randomized patients with HFpEF and obesity (mean BMI 38 kg/m²) to tirzepatide or placebo. Tirzepatide reduced the primary composite endpoint (cardiovascular death or worsening heart failure event) with HR 0.62 (95% CI 0.41-0.95; P=0.026) at 104 weeks and produced a 15.7% mean weight loss. [9] This represents the first prospective randomized evidence of an incretin-based therapy improving hard HF outcomes in the HFpEF phenotype.

Heart Failure With Reduced Ejection Fraction (HFrEF)

GLP-1 receptor agonists have a complicated history in HFrEF. The LIVE trial and FIGHT trial (liraglutide in HFrEF) showed no benefit and a signal toward harm in NYHA class III-IV patients. The FDA label for both tirzepatide and dulaglutide does not list HFrEF as a contraindication, but prescribing in LVEF <40% should involve cardiology review. Dulaglutide's cardiovascular REWIND data included approximately 31% of patients with prior cardiovascular events, but not a dedicated HFrEF subgroup analysis. [4]

Practical Prescribing in Heart Failure

For patients with HFpEF and coexisting obesity, tirzepatide now has the more compelling prospective dataset. For patients with HFrEF or uncertain ejection fraction, dulaglutide's longer safety track record and MACE data from REWIND provide a more established basis for prescribing decisions while tirzepatide's HFrEF-specific data mature.

Pregnancy, Preconception, and Lactation

Contraindication in Pregnancy

Both tirzepatide and dulaglutide are contraindicated in pregnancy. Animal reproduction studies with GLP-1 receptor agonists show dose-dependent fetal growth restriction and skeletal malformations, though human data are limited. The FDA labels for both agents carry this contraindication explicitly and recommend discontinuation at least 2 months before a planned conception given their extended half-lives (tirzepatide t½ approximately 5 days; dulaglutide t½ approximately 5 days). [6, 7]

Polycystic Ovary Syndrome and Fertility

Women with PCOS who use tirzepatide for weight reduction may experience restored ovulatory cycles as adiposity decreases. This is not a trivial clinical detail: pregnancy can occur unexpectedly in women who assumed they were anovulatory. Clinicians prescribing either agent to women of reproductive age should document contraceptive status and counseling at each visit. A 2024 case series published in Fertility and Sterility described spontaneous conception in 6 of 28 women with PCOS-related anovulation who had initiated tirzepatide within 6 months of the conception event. [10]

Lactation

Neither drug has adequate human lactation data. Both FDA labels indicate that animal data show excretion into breast milk and that use during breastfeeding is not recommended given the potential for growth suppression in nursing infants. [6, 7]

Switching Between Zepbound and Trulicity

When Switching From Trulicity to Zepbound Makes Clinical Sense

Patients on dulaglutide who have not achieved HbA1c or weight targets often have room to benefit from the added GIP receptor agonism of tirzepatide. A reasonable approach is to start tirzepatide 2.5 mg the week after the last dulaglutide dose (dulaglutide's once-weekly dosing means no overlap washout is needed), then titrate tirzepatide by 2.5 mg every 4 weeks as tolerated. GI adverse events are additive during transition; pre-emptive dietary counseling reduces the dropout rate.

When Switching From Zepbound to Trulicity Is Appropriate

The HealthRX clinical team uses a four-criterion decision framework for switching a patient from tirzepatide to dulaglutide:

1. Cost access failure. Tirzepatide's list price exceeds $1,000/month without insurance coverage. When manufacturer savings programs are exhausted and prior authorization is denied, dulaglutide at biosimilar-adjacent pricing may be the only viable option.
2. Established MACE risk requiring proven CVOT data now. For a patient with recent ACS or stroke where cardiologists want a drug with completed MACE outcome trial data, dulaglutide's REWIND results (12% relative MACE risk reduction) are available today. Tirzepatide's SURPASS-CVOT has not reported.
3. Persistent GI intolerance at lowest tirzepatide dose. Some patients cannot tolerate even 2.5 mg tirzepatide after two titration attempts. Dulaglutide at 0.75 mg may be better tolerated, though this is not guaranteed.
4. Pregnancy planning within 2 months. Both drugs require discontinuation, but if a patient on tirzepatide is not switching to insulin or metformin, dulaglutide should also be stopped. This criterion applies equally to both directions.

When switching from tirzepatide to dulaglutide, clinicians should expect partial rebound of weight (typically 4-8% of body weight over 6-12 months based on GLP-1 discontinuation data) and upward drift of HbA1c, and document this expectation with the patient before transition. [11]

Transition Dosing Table

| Direction | Last Dose of Drug A | Start Drug B | Starting Dose of Drug B | |---|---|---|---| | Trulicity to Zepbound | Any | Next scheduled injection day | 2.5 mg weekly | | Zepbound to Trulicity | Any | Next scheduled injection day | 0.75 mg weekly | | Either (GI intolerance) | Hold 1-2 weeks | After symptoms resolve | Lowest available dose |

Tolerability and Adverse Event Profiles in Special Populations

Gastrointestinal Side Effects

Nausea, vomiting, diarrhea, and constipation are the dominant adverse events for both drugs. In SURPASS-2 (N=1,879), any GI adverse event occurred in 33-40% of tirzepatide-treated patients across doses vs. 24% with semaglutide 1 mg. Dulaglutide's GI event rates in REWIND averaged approximately 15% over the trial, though REWIND used a single dose (1.5 mg) without escalation. [4] In older adults and CKD patients, GI events carry higher clinical consequence because dehydration and electrolyte shifts are less well-tolerated.

Injection Site Reactions

Both drugs are subcutaneous once-weekly injections. Injection site reactions occur in roughly 3-7% of patients with either agent. Rotating injection sites across abdomen, thigh, and upper arm reduces local reactions.

Thyroid C-Cell Risk

Both agents carry an FDA boxed warning for thyroid C-cell tumors based on rodent data. Neither human pharmacovigilance nor epidemiological studies have confirmed a causal increase in medullary thyroid carcinoma risk in humans to date, but both are contraindicated in patients with personal or family history of MTC or MEN2A/MEN2B. [6, 7]

Cost, Access, and Real-World Adherence

Tirzepatide's average wholesale price in the U.S. Runs approximately $1,059-$1,086/month for Zepbound as of mid-2025. Dulaglutide's list price is approximately $900-$920/month, though generic dulaglutide is not yet available in the U.S. Manufacturer savings cards for both agents can reduce out-of-pocket costs to $25-$150/month for commercially insured patients. Medicare Part D coverage varies; tirzepatide for obesity (non-diabetes indication) is currently excluded from Medicare coverage under most plans due to the OBRA exclusion for weight-loss drugs, while dulaglutide is covered for its diabetes indication. [12]

Adherence at 12 months with once-weekly GLP-1 receptor agonists averages 50-60% in real-world claims data, with the primary discontinuation driver being cost rather than tolerability after the first 3 months. [13]

Summary of Population-Specific Recommendations

| Population | Preferred Agent | Primary Rationale | |---|---|---| | Obesity without T2D | Zepbound (tirzepatide) | Only agent FDA-approved for obesity; 20.9% weight loss in SURMOUNT-1 | | T2D + high MACE risk (CVOT data now required) | Trulicity (dulaglutide) | REWIND 12% MACE reduction; SURPASS-CVOT pending | | T2D + obesity, CVOT flexibility | Zepbound (tirzepatide) | Superior HbA1c and weight reduction | | HFpEF + obesity | Zepbound (tirzepatide) | SUMMIT trial HR 0.62 for CV death/worsening HF | | HFrEF (LVEF <40%) | Cardiology review first | No positive CVOT for either in HFrEF | | CKD G3a-G4 | Either; start at lowest dose | No renal dose adjustment; slower titration advised | | Age ≥65 | Either; monitor lean mass | Tirzepatide has greater efficacy; add protein/exercise | | Pregnancy | Discontinue both | Both contraindicated; stop ≥2 months before conception | | Cost-limited, insurance restricted | Trulicity (dulaglutide) | Lower barrier in some formularies; savings programs |